The pharmacokinetic-pharmacodynamic profile of a fixed 6-g daily continuous intravenous infusion of ceftazidime was assessed in 20 febrile neutropenic patients with acute myeloid leukemia. Mean steady-state ceftazidime concentrations averaging 40 mg/liter from day 2 on ensured maximized pharmacodynamic exposure (values close to four to five times the MIC breakpoint against Pseudomonas aeruginosa). However, large intra- and interindividual pharmacokinetic variability was documented throughout the study period. Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: Helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure / Pea F.; Viale P.; Damiani D.; Pavan F.; Cristini F.; Fanin R.; Furlanut M.. - In: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. - ISSN 0066-4804. - ELETTRONICO. - 49:8(2005), pp. 3550-3553. [10.1128/AAC.49.8.3550-3553.2005]
Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: Helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure
Pea F.;Viale P.;Damiani D.;
2005
Abstract
The pharmacokinetic-pharmacodynamic profile of a fixed 6-g daily continuous intravenous infusion of ceftazidime was assessed in 20 febrile neutropenic patients with acute myeloid leukemia. Mean steady-state ceftazidime concentrations averaging 40 mg/liter from day 2 on ensured maximized pharmacodynamic exposure (values close to four to five times the MIC breakpoint against Pseudomonas aeruginosa). However, large intra- and interindividual pharmacokinetic variability was documented throughout the study period. Copyright © 2005, American Society for Microbiology. All Rights Reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
